Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) reported interim results from its Phase 2 clinical trial of ARCT-032, an experimental inhaled ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE